Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Papillomavirus Infections Clear all
Completed Phase 3 Interventional Results available

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510
View directory record Official record
Conditions
Common Wart
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
1 Year and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
46
States / cities
Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

NCT01461096
View directory record Official record
Conditions
HIV Infections
Interventions
Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Not applicable Interventional Results available

HPV Self-Sampling in Somali Women (Isbaar Project)

NCT05453006
View directory record Official record
Conditions
Cervical Cancer, Papillomavirus Infection, Uterine Diseases, Uterine Cervical Disease
Interventions
COPAN 552c.80 FLOQSwab
Device
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
3,367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 6, 2026, 10:37 AM EDT
Suspended Not applicable Interventional

ORCHID: An Online Intervention for Persons With HIV (Miami)

NCT05935644
View directory record Official record
Conditions
HIV/AIDS, HPV Infection
Interventions
ORCHID
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 6, 2026, 10:37 AM EDT
Terminated Not applicable Interventional

Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy

NCT01609530
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
Liquid Nitrogen Cryotherapy, Pulsed 1064nm Nd:YAG
Procedure
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 6, 2026, 10:37 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

NCT01087164
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Compliance, Message sidedness
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 15 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 6, 2026, 10:37 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

NCT06498661
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

NCT04247282
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Neoplasms
Interventions
M7824, N803, TriAd vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

NCT02748902
View directory record Official record
Conditions
Verruca Vulgaris, Common Warts
Interventions
ingenol mebutate 0.05% gel
Drug
Lead sponsor
Neal D. Bhatia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 6, 2026, 10:37 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Self-Collected Swabs for Primary Human Papilloma Virus (HPV) Screening

NCT05989464
View directory record Official record
Conditions
HPV
Interventions
Self-swab for genital HPV
Diagnostic Test
Lead sponsor
University of Hawaii
Other
Eligibility
25 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03691831
View directory record Official record
Conditions
Common Wart
Interventions
Active, Vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 6, 2026, 10:37 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

PREVENT HPV -Related Cancers Trial

NCT07217145
View directory record Official record
Conditions
HPV Vaccination, Uptake Vaccination, Series Completion
Interventions
PREVENT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

NCT00967785
View directory record Official record
Conditions
Leukopenia, Neutropenia, Infections, Warts, Myelokathexis
Interventions
Mozobil (TM)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 6, 2026, 10:37 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

NCT04708041
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 26 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
14
States / cities
Daly City, California • Oakland, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 6, 2026, 10:37 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reducing Urban Cervical Cancer Disparities

NCT06416150
View directory record Official record
Conditions
Cervical Cancer, Papilloma Viral Infection
Interventions
Stage 1 SOC, Stage 1 HERS, Stage 2 HERS, Stage 2 HERS+HC, Stage 3 SOC, Stage 3 HERS, Stage 3 HERS+HC, Stage 4 HERS, Stage 4 HERS+HC
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

NCT00116662
View directory record Official record
Conditions
Warts
Interventions
Resiquimod
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
3 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Newnan, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 6, 2026, 10:37 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

NCT00501189
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
human papillomavirus vaccine L1, type 6,11,16,18
Biological
Lead sponsor
Eisenhower Army Medical Center
Federal
Eligibility
18 Years to 26 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Gordon, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nanopulse Efficacy Study for the Treatment of Common Warts

NCT02650466
View directory record Official record
Conditions
Common Warts
Interventions
Nanopulse System
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NCT05799157
View directory record Official record
Conditions
Verruca Vulgaris, Warts, Common Wart
Interventions
VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
9 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03202992
View directory record Official record
Conditions
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
27 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 6, 2026, 10:37 AM EDT
Terminated Not applicable Interventional Results available

OPSCC N0 Nodal Control With Reduced IMRT

NCT01891695
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), HPV (Human Papillomavirus)-Associated
Interventions
39.6 Gy radiation
Radiation
Lead sponsor
Paul W. Read, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 6, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00054041
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
Interventions
HspE7, therapeutic conventional surgery, laboratory biomarker analysis
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 6, 2026, 10:37 AM EDT